Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 11/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889809 | 0.80 | MAPT (0.43) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL1894870 | 0.77 | SMN1; SMN2 (0.39) | MAPTMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL1894103 | 0.74 | HSD17B10 (0.42) | MAPTKMT2ASMN1; SMN2LMNACYP2C9 | |
| SCHEMBL1889603 | 0.73 | MEN1 (0.36) | MAPTMEN1RECQLKMT2ASMN1; SMN2 | |
| SCHEMBL10046358 | 0.69 | CYP2D6 (0.35) | MAPTMEN1KMT2ALMNACYP1A2 | |
| SCHEMBL23531275 | 0.65 | RIPK1 (0.34) | MAPTKMT2ALMNACYP2C19CYP2D6 | |
| SCHEMBL23531297 | 0.65 | CYP2D6 (0.34) | MAPTCYP3A4CYP2C19CYP2D6L3MBTL1 | |
| SCHEMBL19990998 | 0.63 | PKM (0.42) | MAPTMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL10595472 | 0.62 | ALDH1A1 (0.40) | MAPTMEN1RECQLKMT2ASMN1; SMN2 | |
| SCHEMBL10341619 | 0.62 | ALDH1A1 (0.40) | MAPTMEN1RECQLKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | claimed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | claimed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | claimed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | claimed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | claimed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | claimed |
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220074-A1 | Compounds for a controlled release of active molecules | ACLY, PTGES, NOTUM | MAPT 2531/4885MEN1 4581/4885RECQL 2247/4885 |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | ACLY, PTGES, PPOX | MAPT 2549/4885MEN1 4691/4885RECQL 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.